Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report
MetadataShow full item record
Citation:Brian J. So et al, "Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report," Journal of Hematology & Oncology 1 (2008), doi:10.1186/1756-8722-1-18, http://www.jhoonline.org/content/1/1/18
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.
Items in Knowledge Bank are protected by copyright, with all rights reserved, unless otherwise indicated.